Eli Lilly stock price slips as Novo Nordisk signals Ozempic, Wegovy list-price cuts
Eli Lilly shares fell 1.3% to $1,045.05 after Novo Nordisk said it will cut U.S. list prices for Ozempic and Wegovy to $675 a month starting January 2027. The move shifts investor focus to drug pricing and margins, despite Lilly’s recent clinical win over Novo’s CagriSema. Barclays slashed its peak sales forecast for CagriSema to $2 billion from $12 billion after new trial data.